Trial Profile
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 02 Jun 2017 Planned End Date changed from 1 Apr 2018 to 10 May 2018.
- 02 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 10 May 2017.
- 02 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment.